Namalwa Cells
General information
Description | Established from the tumor mass of a child with Burkitt Lymphoma. |
---|---|
Organism | Human |
Tissue | Hematopoietic |
Disease | Burkitt lymphoma |
Synonyms | NAMALWA, Namalwa IV, Namalva, NAMALVA, NWA, NK62a |
Characteristics
Age | Child |
---|---|
Gender | Female |
Morphology | Round cells |
Cell type | B lymphocyte |
Growth properties | Suspension |
Identifiers / Biosafety / Citation
Citation | Namalwa (Cytion catalog number 300439) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Products | IG-M |
---|---|
Karyotype | 2n = 46 |
Handling
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 2 x 10^5 cells/ml and keep the cell concentration within the range of 1 x 10^5 to 1 x 10^6 cells/ml for optimal growth. |
Seeding density | 1 x 10^5 cells/mL |
Fluid renewal | 2 times per week |
Freezing recovery | Fast |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,y
CSF1PO: 10,11
D13S317: 11,12
D16S539: 9
D5S818: 12,13
D7S820: 11
TH01: 7,9.3
TPOX: 6,11
vWA: 14
D3S1358: 16
D21S11: 27,28
D18S51: 15
Penta E: 5,15
Penta D: 8,13
D8S1179: 13,15
FGA: 22
|
HLA alleles |
A*: 03:01:01, 20:02:01
B*: 07:02:01, 01:01:01
C*: 07:01:02, 07:02:01
DRB1*: 04:05:01, 15:03:01
DQA1*: 01:02:01, 03:03:01
DQB1*: 03:02:01, 06:02:01
DPB1*: 01:01:01, 02:01:02
E: 01:03:02
|